FDA Finds Beckman Coulter Troponin Test Modified Without Proper Clearance
This article was originally published in The Gray Sheet
Executive Summary
Beckman Coulter will likely need to restrict use of its AccuTn1 troponin test kit in response to FDA findings that the firm modified the assay without proper clearance, the company said March 22
You may also be interested in...
Beckman CEO Resigns As Company Faces Regulatory Challenges
Beckman Coulter announced the resignation of Scott Garrett as chairman, president and CEO Sept. 7 as the firm tries to recover from a recent FDA-triggered diagnostic test market withdrawal and ongoing regulatory scrutiny
Beckman CEO Resigns As Company Faces Regulatory Challenges
Beckman Coulter announced the resignation of Scott Garrett as chairman, president and CEO Sept. 7 as the firm tries to recover from a recent FDA-triggered diagnostic test market withdrawal and ongoing regulatory scrutiny
Beckman Coulter Pulls Troponin Assays From Market
Beckman Coulter is pulling a portion of its cardiac troponin assays from the market in response to FDA scrutiny, the firm said April 12